ArticleJournal of cellular and molecular medicine2025
New Diagnostic and Therapeutic Targets for Spinal Cord Injury: GRN Gene.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New Diagnostic and Therapeutic Targets for Spinal Cord Injury: GRN Gene.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Spinal cord injury (SCI) is a severe disabling disease due to the poor self-healing of the central nervous system. Studies showed that many N6-methyladenosine (m6A) RNA methylation profiles are hypomethylated after SCI, which are related to neural regeneration and different m6A marker genes. In addition, immune cell infiltration may significantly affect the development and progression of SCI. Therefore, we attempted to identify the correlation between SCI-related biomarkers and m6A methylation regulators in order to classify them. To this end, we collected two gene expression profile datasets (GSE464 and GSE45006) from the GEO database, performed differential expression analysis between pairs before and after SCI, and identified 19 constant differentially expressed genes (DEGs). We found that the constant differential genes were strongly correlated with m6A methylation regulators, which could modulate the immune microenvironment of SCI. Next, this paper used a consensus clustering algorithm to classify SCI patients into three subtypes. There are significant differences between 19 constant DEGs and 28 immune cells among different subtypes. Finally, the correlation analysis of the intersection genes between constant DEGs and immune genes was performed, and GRN was identified as a potential immune biomarker for SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.